Related Experiment Video
Updated: Jul 14, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Bacteraemic pneumococcal pneumonia: impact of HIV on clinical presentation and outcome
Charles Feldman1, Keith P Klugman, Victor L Yu
1Division of Pulmonology, Department of Medicine, Johannesburg Hospital, University of the Witwatersrand, Medical School, 7 York Road, Parktown 2193, Johannesburg, South Africa. feldmanc@medicine.wits.ac.za
Objectives:
The objectives of this study were to investigate the clinical and laboratory features, hospital course and outcome of patients with bacteraemic pneumococcal pneumonia, comparing HIV with non-HIV patients, as well as HIV patients from different parts of the world.
Methods:
This was a multicentre prospective observational study of consecutive adult cases with bacteraemic pneumococcal pneumonia in 10 countries on 6 continents.
Results:
A total of 768 cases were recruited, of which 200 were HIV-infected; 166 were from South Africa. Lower age, i.v. drug use, fewer co-morbid illnesses, and a higher frequency of respiratory symptoms were significantly more likely to occur in HIV patients. The 14-day mortality for the group as a whole was 14.5%, being 16% in the HIV patients and 13.9% in the non-HIV patients (not significant). When adjustments were made for age and severity of illness, HIV patients had significantly higher 14-day mortality with significant trend for increasing 14-day mortality in those with lower CD4 counts. Despite differences in various clinical and laboratory parameters in patients from different parts of the world, on multivariate analysis, when adjusting for regional differences, the HIV-infected patients were still noted to have poorer 14-day mortality.
Conclusions:
This study, in contrast to previous investigations, indicates that there are significant differences in the clinical presentation and outcome of bacteraemic pneumococcal pneumonia when comparing HIV and non-HIV patients.
More Related Videos
13:50Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients
Published on: June 11, 2011
07:21Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
Published on: June 23, 2019
Related Concept Videos
Cryptococcal Meningitis
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia II: Pathophysiology